ESMO 2022: Breast and ovarian trial analysis

ESMO 2022: Highlights, commentary and analysis

Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

ESMO 2022: Renal roundup

Fruquintinib provides improvement in overall survival for refractory mCRC

ESMO 2022: Breast cancer highlights

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO

Emerging systemic therapies in rare urothelial cancer variants

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data